The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.
John P. Neoptolemos, MA, MB, BChir, MD
Advertisement
Articles by John P. Neoptolemos, MA, MB, BChir, MD
Advertisement
Latest Updated Articles
ESPAC-4: Adjuvant Gemcitabine/Capecitabine in Resected Pancreatic CancerPublished: June 14th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
3
FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma
4
Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC
5
